Answers are grounded in this paper and cite their sources.
Background : Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease. While resmetirom and semaglutide recently gained approval, effective therapies for MASH-related compensated cirrhosis (F4) remain lacking. This study systematically characterizes the global MASH trial portfolio to outline developmental trends and guide future trial design. Method : We analyzed the Informa repository for interventional MASH trials registered through December 2025. Excluding observational studies, 893 trials were included. Trial metadata, mechanisms of action (MOAs), patient inclusion criteria, endpoints, and diagnostic modalities were extracted and independently verified. Findings : The US (n=337) and China (n=115) led global registrations. GLP-1 receptor agonists (82) and FXR agonists (72) dominated mechanistic exploration, though only 41% of Phase III trials completed. Notably, negative-outcome trials enrolled significantly more F4 patients than successful trials (36.4% vs. 17.8%; P=0.024). Post-2020, GLP-1 agonists superseded FXR agonists in pipeline dominance. We identified 38 mid-to-late-stage combination trials, four completing with positive outcomes. Cardiometabolic endpoint integration surged from ~65% (2010) to >90% (post-2023), alongside increased adoption of non-invasive biomarkers. Conclusion : The MASH therapeutic pipeline is pivoting toward systemic, multi-mechanistic combination strategies integrating cardiometabolic co-management and non-invasive precision diagnostics. These insights inform the rational design of next-generation therapeutics for advanced disease.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: